Navigation Links
Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform

LAUSANNE, Switzerland, December 5, 2012 /PRNewswire/ --

Biocartis launches its revolutionary detection platform, Dynamic Multi-Analyte Technology ("DMAT"):

  • New proteomic and nucleic acid platform provides ultra-high quality data analysis even at higher multiplex formats.
  • Platform launched well ahead of plan. Biocartis flips from a late-stage development company into a commercial business. 

Accurate and fast validation of biomarkers; increasing efficiency in Research and Drug Development

DMAT is an innovative and integrated detection platform for high-quality biomarker analysis. It enables accelerated development of multiplex assays where several biomarkers can be analyzed at the same time. DMAT dramatically reduces hands-on time and allows users to perform bioassays far more quickly and cost-effectively than with other systems, while ensuring optimal accuracy.

"This revolutionary technology will accelerate the conversion of biomarker discoveries into clinical practice and will help scientists deliver more quickly the promise of personalized medicine," said Biocartis CEO Dr. Greg Parekh. "DMAT is complementary with protein biomarker discovery and next generation sequencing, because the ease of use, sensitivity and accuracy enables rapid validation of new biomarkers initially identified on these other platforms."

Innovative detection technology combining reproducibility, speed and multiplexing

Conceived in 2007 and developed under design control, DMAT leverages advanced semi-conductor technologies and micro-fluidics to provide fast, flexible and multiplexed detection and quantification of nucleic acid and protein based biomarkers. The platform accelerates biomarker research and yields robust and highly reproducible data over a wide range of analyte concentrations. Demonstrating concordance between single-plex and multiplex assays, the DMAT platform can measure over 2000 analytes simultaneously without deterioration in performance.

For Research Use Only ("RUO")

The DMAT platform is initially targeting the research market. As such, Biocartis is offering customizable generic test consumables to maximize application flexibility. Biocartis is additionally developing a menu of important RUO assays including a cytokine panel, an oncogene panel and a cell signaling panel.

With the commercialization of DMAT, Biocartis is scaling up its sales force to initially target the Preclinical, Clinical Development and Clinical Research markets.

SOURCE Biocartis
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Biocartis Names Dr. Nayan Gregory Parekh As Chief Executive Officer
2. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
3. Chemical Publishing Company Announces its Niche Catalog in the Water Technology and Water Treatment Space
4. Japan Bioinformatics Announces Study on Leading Mapping Tools for DNA Mutation Discovery
5. The Scientist Proudly Announces the Top 10 Innovations of 2012
6. Bayer CropScience Announces LibertyLink LinkUp Offer Increased for 2013 Season
7. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
8. Genomic Health Announces Presentation of Six Studies at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
9. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
10. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
11. Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinsons Disease
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract research, ... improve patient outcomes and quality of life, will now be offering its impurity ... to new regulatory requirements for all new drug products, including the finalization of ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
Breaking Biology News(10 mins):